NZ334164A - Process to produce solid homeopathic compositions - Google Patents
Process to produce solid homeopathic compositionsInfo
- Publication number
- NZ334164A NZ334164A NZ334164A NZ33416497A NZ334164A NZ 334164 A NZ334164 A NZ 334164A NZ 334164 A NZ334164 A NZ 334164A NZ 33416497 A NZ33416497 A NZ 33416497A NZ 334164 A NZ334164 A NZ 334164A
- Authority
- NZ
- New Zealand
- Prior art keywords
- solid
- homeopathic
- solution
- process according
- radiation
- Prior art date
Links
- 239000007787 solid Substances 0.000 title claims abstract description 54
- 230000001632 homeopathic effect Effects 0.000 title claims abstract description 53
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 238000000034 method Methods 0.000 title claims description 49
- 239000000243 solution Substances 0.000 claims abstract description 81
- 239000012895 dilution Substances 0.000 claims abstract description 49
- 238000010790 dilution Methods 0.000 claims abstract description 49
- 239000003085 diluting agent Substances 0.000 claims abstract description 14
- 239000002245 particle Substances 0.000 claims abstract description 13
- 238000004519 manufacturing process Methods 0.000 claims abstract description 12
- 150000001875 compounds Chemical class 0.000 claims abstract description 7
- 238000007865 diluting Methods 0.000 claims abstract description 6
- 230000005855 radiation Effects 0.000 claims description 25
- 238000002360 preparation method Methods 0.000 claims description 18
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 claims description 11
- 229910052722 tritium Inorganic materials 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 238000004806 packaging method and process Methods 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 7
- 238000003860 storage Methods 0.000 claims description 6
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 4
- 239000012876 carrier material Substances 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
- YTBSYETUWUMLBZ-QWWZWVQMSA-N D-threose Chemical compound OC[C@@H](O)[C@H](O)C=O YTBSYETUWUMLBZ-QWWZWVQMSA-N 0.000 claims description 2
- 239000004411 aluminium Substances 0.000 claims description 2
- 229910052782 aluminium Inorganic materials 0.000 claims description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 2
- 229910052802 copper Inorganic materials 0.000 claims description 2
- 239000010949 copper Substances 0.000 claims description 2
- 229910052759 nickel Inorganic materials 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- -1 threalose Chemical compound 0.000 claims description 2
- 239000003643 water by type Substances 0.000 claims description 2
- URYAFVKLYSEINW-UHFFFAOYSA-N Chlorfenethol Chemical compound C=1C=C(Cl)C=CC=1C(O)(C)C1=CC=C(Cl)C=C1 URYAFVKLYSEINW-UHFFFAOYSA-N 0.000 claims 1
- 239000008187 granular material Substances 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- 235000011468 Albizia julibrissin Nutrition 0.000 description 3
- 241001070944 Mimosa Species 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 229940098465 tincture Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 235000013681 dietary sucrose Nutrition 0.000 description 2
- 239000003061 homeopathic agent Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940126601 medicinal product Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 241000227129 Aconitum Species 0.000 description 1
- 206010042618 Surgical procedure repeated Diseases 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 125000005909 ethyl alcohol group Chemical group 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The process for preparing a homeopathic medicinal composition in a solid form comprises: a) providing an initial solution containing a predetermined starting concentration of a selected compound having homeopathic efficacy; b) diluting the initial solution using at least one dilution step by addition of diluent so as to produce following the or each dilution step a diluted solution having a higher dilution than that of the solution being diluted and c) dosing a compacted mass of particles of a solid carrier with a predetermined amount of the resulting diluted solution so as to produce a solid homeopathic medicinal composition in a compacted solid form.
Description
%
Intellectual Property Office of New Zealand IP Summary Report
Page: 1 of 1 Date: 02 June 2000 Time: 14:16:58 (Iprip02 2.00.23)
(51) Classification: A61K9/16, A61K9/20
IPC Edition: IPC
Statlus: 70 Accepted
Client Ref: JB211547
334164
Version number 4 IP type: Patent PCT Inward
(86) International Application number: GB97/02220
(87) WO Publication number: 98/07411 Elected: Y
(22) NZ Filing date: 15 August 1997 Date entered National phase: *.2 February 1999 (30) Priority Data: (31)96 9617658 (32) 23 August 1996 (33) GB
(71) Applicant: DYNSOL LTD, Britannia Buildings, St Peter's
Street, Huddersfield, West Yorkshire HD11BB, Unitef Kingdom
(72) Inventors: Ccnte, Rolland Rene
Lasne, Yves
Contact: BALDWIN SHELSTON WATERS, Level 14, NCR House, 342 Lambton Quay, Wellington, NZ
Primary Examiner: JENNY JEBSON Journal: 1452
Office title: Process to produce solid homeopathic compositions (54) Applicant title: Process to produce solid homeopathic compositions
Date actions completed: Application Accepted Next renewal date:
02 June 2000 15 August 2001
" End of report"
1
PROCESS TO PRODUCE SOLID HOMEOPATHIC COMPOSITIONS
This invention relates to a process for the production of homeopathic medicines.
Homeopathic medicine is a system of healing which has 5 been in existence since 1796. The word homeopathy comes from the Greek language and may be translated as "similar suffering". In other words an agent which can cause disease m a healthy person can be used to therapeutic advantage in a person who is sick and whose symptoms resemble those of the 10 agent. Normally the agent is administered to a pati"ent in minute amount and in very high dilution, in contrast to the practice in allopathic medicine in which the therapeutic agent is normally administered to a patient in much higher amount and at a much higher concentration.
The agent can be administered in the form of a solution,
as an ointment or paste, as tablets, or in the form of pellets or globules of a carrier, such as lactose, which has been impregnated with a dilute solution of the agent. Alternatively it is possible to triturate the agent with a 20 solid carrier. A typical size for pellets is around 200 per gram, while globules typically come in a size of about 20 per gram. Tablets may be of any suitable size which are conve-' ent for sucking for example about 0.2 g to about 1 g. o principal methods are used for dilution of a 25 substance so as to lower its concentration in a given product, whether liquid or solid. In the firsc method, which was developed by the German physician and experimental pharmacologist Samuel Hahnemann (1755-1843), multiple flasks are used. The second method is one developed by Hahnemann's 30 contemporary, Simeon N. Korsakoff and involves use of a single flask.
The Hahnemannian process consists in effecting dilutions in separate flasks or bottles. To make a one hundred fold
SUBSTITUTE SHEET (RULE 26)
Printed from Mimosa
dilution, 1% by volume of a starting solution (or mother tincture) of a convenient concentration, for example about 1 g per litre, is placed in a flask and mixed with 95% by volume of diluent. The resulting diluted mixture has a 5 Hahnemannian Concentration which, for convenience, can be designated 1 CH. To make a further dilution, 1% by volume of this 1 CH solution is again mixed with 99V by volume of diluent. The resulting diluted solution can be designated 2 CH. These operations can be carried out N times to obtain a 10 solution of the Nth C"..
The Korsakoviar. process is undertaken in a single bottle or flask. In this case 99% cf a starting solution (or mother tincture) is drained cr aspirated from the bottle or flask and the remaining l*« by volume is diluted by pouring in 99% 15 by volume cf the diluent. After mixing thy resulting solution can, for convenience, be designated the first Korsakovian centesimal (or 1 cmK). Upon repeating the procedure with the 1 crr.K solution a further diluted solution, i.e. the 2 crr.K solution, is obtained. By carrying out the 20 procedure N times the Nth cmK solution can be obtained.
Whilst dilutions of 1 in 100, i.e. centesimal dilutions, are common, anotner accepted method of dilution is the decimal method in which 1 part of the mother tincture is diluted to 1/10 of its original strength.
The number of operations that require to be carried out in order to reach a desired level of dilution can be summarised as shown in Table 1 below. The starting concentration is a convenient concentration, such as 1 g per litre.
SUBSTITUTE SHEET (RULE 26)
Printed from Mimosa
->
J
TABLE 1
Dilut ion
Concentration
Decimal Scale
Centesimal Scale in 1/100
in l0 n
1/10
/100
-'
1 D
1/100
1/100
"J
2 D
1 CH
1/1000
0 .1/100
°
3 D
1/10000
0 . 01/100
"'
4 D
2 CH
1/100000
0.001/100
"s
D
1/1000000
0.0001/100
'
6 D
3 CH
"
9 CH
-60
3 0 CH
In his writings Hahnemann recommended that utensils used for the preparation of a homeopathic medicinal preparation IS should be sterilised in boiling water. He also recommended that, in order to have a correct succussion effect in diluting a solution, the bottle should be large enough to be only two thirds filled up. In order to develop the dynamic pharmaceutical virtues of the preparations, the bottle should 20 be submitted to a series of strong succussions. Typically this should involve pounding the bottle filled to 75% or 50% with the solution on a thick book having a leather cover 100 times at the frequency of the heart's beat. Furthermore the prepared solutions should be stored and protected from th>j 25 sun and the daylight in a well sealed bottle.
In the conventional method of preparing homeopathic medicines in solid form the final dilution step is typically achieved by spraying a measured amount of an appropriately diluted solution, for example, a 30 CH solution, onto a mass 30 of granules of a carrier of known weight contained in a rotating flask. In this way the granules become randomly
SUBSTITUTE SHEET (RULE 28)
Printed from Mimosa
33 416'
4
impregnated with the solution. Typically the quantity of solution corresponds to at most about 2 or 3 % w/w of the .weight of the granules. The end result may be that some of the granules become saturated with the solution, while others 5 remain totally dry. Although some improvement can be obtained by changing the direction of rotation of the flask during spraying, for example, after about approximately one third of the spraying operation has been completed and again after about two thirds of the solution has been sprayed on 10 the mass of granules, the end result is still unsatisfactory in that it cannot be assured that every granule shall be uniformly impregnated with the solution.
It would accordingly be desirable to provide a process for the production of solid forms of homeopathic medicines in 15 which the product is reliably impregnated with the final diluted solution. It would further be desirable to provide a process for preparing solid forms of homeopathic medicinal preparations which can enable the reliable production, preferably on an industrial scale, of solid homeopathic 20 medicinal preparations with reproducible effects. It would further be desirable to provide a homeopathic medicinal product in a solid form which, it can be ensured, will reach the patient in optimal condition and with its efficacy undiminished.
It is accordingly an object of the present invention to provide a process for the production of solid forms of homeopathic medicines in which the product is reliably impregnated with the final diluted solution, or at least provide the public with a useful alternative. It is a 30 further object of the present invention to provide a process for preparing solid forms of homeopathic medicinal preparations which can enable the reliable production, preferably on an industrial scale, of solid homeopathic
INTELLECTUAL property office OF n.z.
1 1 MAY 2000
33 4 1 6
medicinal preparations with reproducible effects, or at least provide the public with a useful alternative. It is yet a further object of the invention to provide a homeopathic medicinal product in a solid form which, it can be ensured, 5 will reach the patient in optimal condition and with its efficacy undiminished, or at least provide the public with a useful alternative.
According to the present invention there is provided a process for preparing a homeopathic medicinal composition in 10 solid form which comprises:
(a) providing an initial solution containing a predetermined starting concentration of a selected compound having homeopathic efficacy;
(b) diluting the initial solution using at least one 15 dilution step by addition of diluent so as to produce following the or each dilution step a diluted solution having a higher dilution than that of the solution being diluted;
and
(c) dosing a compacted mass of particles of a solid
carrier with a predetermined amount of the resulting diluted solution so as to produce a solid homeopathic medicinal composition in compacted solid form.
Preferably the compacted mass of particles of a solid cavrier is a tablet or globule comprising the solid carrier. 25 A suitable weight for the tablets is about 0.15 g each. Globules can, for example, weigh about 0.05 g each.
The process may further include the step of packaging the resulting solid homeopathic medicinal preparation in a container adapted to protect the solid homeopathic medicinal 30 composition from 3" radiation, including emitted 3" radiation in the tritium energy range, until required for consumption by a patient.
In a particularly preferred process according to the intellectual property office of nz
1 1 MAY 2000
ncr*ci\/cn
' /. 1 £: w %J ' i* I 0
invention the compacted mass of particles of the solid carrier is placed in a packaging container prior to effecting, the dosing step.
The dilution step may comprise succussion of the diluted 5 solution during or after each dilution stage.
Preferably the dilution step, any succussion step, and the dosing step, as well as packaging are carried out within an environment shielded from 3" radiation, including emitted 3" radiation in the tritium energy range. 10 The compound having homeopathic efficacy may be any agent conventionally used in homeopathic medicine.
In the process of the invention, in the or each dilution step, the diluent generally comprises a solvent, such as water, ethyl alcohol, or a mixture thereof. The diluent 15 preferably comprises water in all dilution .steps except the la3t one,- however, in the last dilution step to produce the diluted solution for use in the dosing step (c) re diluent preferably comprises ethyl alcohol.
In one form of the process the dilution otep (b) is 20 repeated a plurality of times prior to the dosing step (c)
which constitutes a final dilution step. In the dosing step (c) there is preferably used a diluted solution which has been prepared using a final dilution step wherein the diluent is ethyl alcohol.
A typical solid carrier material comprises a carbohydrate, such as a saccharose, for example lactose, sucrose, threalose, threose, or the like. A mixture of saccharoses can be used. The solid carrier material is preferably formed into tablets weighing, for example, from 30 about 0.2 g up to about 1 g or more, e.g. up to about 2 g.
Shielding is effected so as to shield from 3" radiation, including emitted 3" radiation in the tritium energy range.
INTELLECTUAL property officl: of n.z.
I 1 MAY 2000
1
In other words the shielding should be effective to prevent penetration of 3"particles. In order to provide the necessary snielding during the dilution step, any succussion step, the dosing step and packaging, these operations can be carried out inside a Faraday cage. Normally such shielding will also be effective to prevent penetration by a particles; it is, however, impractical to attempt to provide shielding against y rays. The shielding step is preferably carried so as to shield from 3" radiation having energy in the range of up to about 19 keV. In particular, the shielding step can be carried out so as to shield from 3" radiation energy in the range of from about 1 keV to about 19 keV.
The container in which dosing of the tablet or other compacted mass of the carrier is carried out and in which the homeopathic medicinal composition may be eventually distributed to practitioners or customers is desirably substantially impervious to 3' radiation, including emitted 3" radiation in the tritium energy range. Such a container may be made from a paramagnetic metal. Alternatively it may comprise a composite container comprising an inert inner container and an outer shield substantially impervious to 3' radiation, including emitted 3' radiation in the tritium energy range. Suitable metals from which to form the storage container are, for example, aluminium, nickel or copper.
The dilution step (b) preferably includes a succussion step. Succussion can be imparted manually; in this case the succussion should preferably be carried using a gloved hand so as not to supply heat to the flask or other container during succussion. Alternatively the fla3k or other container can be succussed mechanically. It is desirable to avoid stirring the solution during succussion in such a way as to produce a vortex. A suitable succussion regimen involves shaking the flask or other container mechanically at imcLLcuuAL property office of hz.
" MAY 2000
8
33 4164
a frequency in the range of from about 0.1 Hz to about 60 Hz with an amplitude of about 4 0 mm for a period of about 10 seconds. Whilst succussion is desirable, it should not be so vigorous as to impart energy to the solution of more than 5 about 85000 kJ/mole.
In another aspect the invention provides a homeopathic medicinal preparation which has been prepared according to the process of the invention.
The invention further provides a storage container which 10 is adapted to shield its contents from the effects of 3" radiation, including emitted 3" radiation in the tritium energy range, containing a charge of a solid homeopathic medicinal preparation containing an agent having homeopathic efficacy, which preparation has been prepared by a process 15 which comprises:
(a) providing an initial solution containing a predetermined starting concentration of a selected compound having homeopathic efficacy;
(b) diluting the initial solution using at least one 20 dilution step by addition of diluent so as to produce following the or each dilution step a diluted solution having a higher dilution than that of the solution being diluted;
and
(c) dosing a compacted mass of particles of a solid
carrier with a predetermined amount of the resulting diluted solution so as to produce a solid homeopathic medicinal composition in compacted solid form.
Conveniently the storage container is adapted to contain a unit dosage of the homeopathic medicinal composition, for 30 example one or more tablets or from three up to twenty one, in multiples of three, globules. This means that, when the patient opens the container in readiness for taking the unit dosage, there is no risk of any subsequent dosage being init, '-ectual property office of n1.
< I MAY 2009
"53 4 I o 4
exposed to the effects of radiation such as would occur if the container contained more than one unit dosage of the homeopathic medicinal composition and were opened by the patient. There is also no risk of the contents of the 5 container, in this case, being influenced by the contents of another container with a homeopathic preparation of another strength or containing a different homeopathic agent. Such a container can be a screw capped container, a container with a childproof cap, a container with a slide-off cap, a sealed 10 ampoule with a frangible tip, or a bag made of a metallised plastics material. The container may be provided with a tamperproof seal of conventional design so as to indicate to the patient that the homeopathic medicinal preparation contained therein h;js remained shielded from (5" radiation, 15 including emitted 3" radiation in the tritium energy range, since packaging was effected.
In the dilution step the conventional dilution methods of Hahnemann or of Korsakoff can be used in which the initial solution, which is of any convenient strength, is diluted by 20 a factor of one hundred or ten at each dilution stage.
Alternatively the initial solution can be diluted by a method (which we have termed the GCL method) which involves dilution in a first dilution step by a factor of 100 and mixing by succussion. In ouch a succussion step the flask should be 25 shaken a number of times in the same direction, e.g.
horizontally or vertically, in order to introduce into the diluted solution energy in the range of, for example, from about 10 3 to about 200 J/g. This solution can be termed a 1 G solution. Then the succussed diluted solution resulting 30 from such a first dilution step is diluted by discarding one fifth of its volume and replacing the discarded volume with further diluent and again succussing the resulting solution. This resulting solution can be termed a 2 G solution. The
■ECTUAL property office OF n.2.
< t MAY 2000
3k) 4 I U £'
concentrations in the resulting solution are set out in Table 2 below.
TABLE 2
Dilution
Concentration
GCL
in 1/100
in 10"n
Scale
1/100
1/100
2
1 G
8/1000
0. 8/100
8 x 1CT3
2 G
64/10000
0.64/100
64 x 10"4
3 G
512/100000
0.512/100
512 x 10"s
4 G
4096/1000000
0 .4096/100
4096 x 10'6
G
Id
A molar solution of a substance contains, according to accepted molecular theory, 6 . 0 2 3 x 1023 molecules (i.e. Avogadro's number of molecules) of that substance per litre. Hence conventional scientific wisdom would suggest that, even if one were to commence with an initial solution of molar strength, a 10"60 molar solution (or a 30 CH solution) of a substance contains statistically less than 1 molecule per litre of that substance. Nonetheless there is evidence to suggest that a beneficial homeopathic effect can be observed in a patient, in a suitable case, who has been treated with a 30 CH solution of a given homeopathic agent.
The applicants postulate that, in contrast to the usually accepted theory which suggests that mass is uniformly distributed in the space-time continuum, in fact mass is non-uniformly spread in the space-time continuum and so non-existing in the cone of the future of a point. Within this theoretical framework it can be calculated mathematically and verified experimentally by use of so-called contonian statistics that, in the cone of the future where a particle disappears, a non-trivial physical field appears; this can be termed the remanent wave. A remanent wave is always created in^'-lfctual property office of nz
< I MAY 2000
11
when a particle disappears and leaves what can be termed a "white hole". It is further postulated that, at any Hahnemannian dilution, remanent waves and so-called hyperprotons are created, which take over and reorganise the 5 structure of the diluent.
For further information regarding the mathematical calculations involved in contonian statistics reference may be made to interpretation physico-wathematigue de 1'effet pharmacologique des hautes dilutions: onde remanente 10 apparences contoniennes (conton) by H. Berliocchi & R. R. Conte, Cahiers de Biotherapie, No. 126, pages 73 to 80 (1994) .
In the process according to the invention at least one tablet or globule or other compacted mass of solid carrier 15 can be placed in a container and impregnated with a suitable amount of the diluted solution. In the case of globules, it may be desirable to place three globules in the container; if tablets are used, then a single tablet can be placed in the container. Next a suitable amount, for example, a drop, of 20 the diluted solution can be allowed to fall on to each globule or tablet. Then a further set of globules, e.g. a further three globules, or a further tablet, can be placed in the container, preferably on top of the first treated set of globules or tablet, and dosing repeated. This procedure can 25 be repeated as many times as desired until the container contains the desired quantity of globules or tablets.
In a particularly preferred process according to the invention, the tablets are each a snug fit in the cross section of the open container. If globules are used, then 30 the container is preferably sized so that a predetermined number of aligned globules are a snug fit in the cross section of the open container.
The container is desirably elongate and of substantially intellectual property office of nz
< I MAY 2000
rectangular cross section. The tablets or globules are sized so as to fit snugly in the container as described above.
In order that the invention may be clearly understood and readily carried into effect, a preferred process according to the invention will now be described, by way of example only, with reference to the accompanying drawings, wherein:-
Figure 1 is a diagram illustrating a conventional method of impregnating granules or globules;
Figure 2 is a cross section of a container containing three globules; and
Figure 3 is a diagram illustrating a dosing step of a process for preparing solid homeopathic medicinal compositions according to the invention.
Referring to Figure 1 of the drawings, in a conventional process for the production of a solid homeopathic medicinal composition, a mass 1 of, for example, from about 10 g to about 2 0 kg, for example about 4 kg of granules or globules of a solid carrier, such as a carbohydrate, is placed in a flask 2 which is rotateu about its axis 3 as indicated by arrow 4. Whilst so rotating the flask 2 and its contents, i.e. the mass 1, a diluted solution 5 of appropriate strength of a compound having homeopathic efficacy, for example a 30 CH solution, is sprayed into the flask 2 from a container 6 through an atomiser 7. The resulting spray 8 of atomised droplets of the solution 5 is directed into the interior of flask 2. After approximately one third of the solution 5 has been sprayed into flask 2, the direction of rotation of flask 2 is reversed and spraying is continued. After about two thirds of the final volume of solution has been sprayed into flask 2, the direction of rotation is again reversed.
In a typical procedure the weight of solution 5 sprayed into flask 2 corresponds to about 2.5% w/w based upon the intellectual propehty office
OF NZ
I I MAY 2000
RPfCiwcn
4 16 4
13
weight of the globules or granules 1.
Figure 2 illustrates a container 9 which contains three globules 10. Container may be elongated so as to contain, for example, seven rows of globules each weighing typically 5 0.05 g each. If the dosage is appropriately controlled, then it can be arranged that the patient can consume one globule three times a day; if the container 9 contains seven rows each of three globules, then the patient will have a supply of globules 10 sufficient to last him or her for a total of a 10 week.
To prepare the globules according to the process of the invention a drop of appropriate dilution is dropped on to each globule 9 in a first row and then a further row of globules 10 is inserted into the container 9 and the 15 procedure repeated.
Figure 3 shows a container 11 with two tablets 12 and 13 therein. Tablet 12 is inserted first and then dosed by allowing a drop of an appropriately diluted solution, for example, a 30 CH solution of aconitum to fall from a needle 20 14 on to tablet 12. Then tablet 13 is placed on top of tablet 12 and the procedure is repeated. A further tablet or tablets (not shown) can be placed on top of tablet 13 and the dosing procedure again repeated. When the desired number of tablets has been so treated, a closure member (not shown) can 25 be put on the container to continue the packaging procedure.
As will be appreciated by those skilled in the art, the process can be readily automated with containers being moved in an array on a conveyor belt in turn through a tablet inserting station at which a first tablet 12 is inserted into 30 each container 11, then through a first dosing station at which a multiple needle dispensing device doses an appropriate amount of a diluted solution on to the tablets 12, then through a second tablet insertion station for intellectual property office of nz
11 MAY 2000 RECPIVFn
33^6
14
addition of tablets 12 and through a further dosing station, and so on, as necessary, and eventually through a package closure station at which a closure is placed on the container 11 or in which container 11 is other wise sealed.
Multiple dosing apparatus suitable for use in the practice of the invention is well known, for example, in the field of medical diagnosis and in microbiology for dispensing small quantities of liquid into multiple wells of a multiple well plate or can readily be adapted therefrom.
intellectual property office of nz
1 I MAY 2000 RECEIVED
Claims (18)
1. A process for preparing a homeopathic medicinal composition in solid form which comprises: (a) providing an initial solution containing a predetermined starting concentration of a selected compound having homeopathic efficacy; (b) diluting the initial solution using at least one dilution step by addition of diluent so as to produce following the or each dilution step a diluted solution having a higher dilution than that of the solution being diluted; and (c) dosing a compacted mass of particles of a solid carrier with a predetermined amount of the resulting diluted solution so as to produce a solid homeopathic medicinal composition in compacted solid form.
2. A process according to claim 1, in which the compacted mass of particles of ? ^olid carrier a tablet or globule comprising the solid carrier.
3. A process according to claim 2, in wi ich the tablet weighs about 0.15 g.
4. A process according to claim 2, in which the globules weigh about 0.0 5 g each.
5. A process according to any one of claims 1 to 4, which further includes the step of packaging the resulting solid homeopathic medicinal preparation in a container adapted to protect the solid homeopathic medicinal composition from 3" radiation, including emitted 3" radiation in the tritium energy range, until required for consumption by a patient.
6. A process according to any one of claims 1 to 5, in which the compacted mass of particles of the solid carrier is placed in a packaging container prior to effecting the dosing step.
7. A process according to any one of claims 1 to 6, in intellectual property office of nz 12 FEB 1999 16 which the dilution step comprises succussion of the diluted solution during or after each dilution stage.
8. A process according to any one of claims 1 to 7, in which the dilution step, any succussion step, and the dosing step, as well as packaging are carried out within an environment shielded from (3~ radiation, including emitted (3~ radiation in the tritium energy range.
9. A process according to any one of claims 1 to 8, in which the solid carrier material comprises a carbohydrate.
10. A process according to claim 9, in which the carrier material comprises lactose, sucrose, threalose, or threose.
11. A process according to any one of claims 1 to 10, in which the container in which dosing of the tablet or other compacted mass of the carrier is carried out and in which the homeopathic medicinal composition is eventually distributed to practitioners or customers is substantially impervious to radiation, including emitted 3" radiation in the tritium energy range.
12. A process according to claim 11, in which the container is made from a metal selected from aluminium, nickel or copper.
13. A solid homeopathic medicinal preparation which has been prepared by a process according to any one of claims 1 to 12.
14. A storage container which is adapted to shield its contents from the effects of (3" radiation, including emitted 3" radiation in the tritium energy range, containing a charge of a solid homeopathic medicinal preparation containing an agent having homeopathic efficacy, which preparation has been prepared by a process which comprises: (a) providing an initial solution containing a predetermined starting concentration of a selected compound having homeopathic efficacy; (b) diluting the initial solution using at least one intellectual property office of nz 12 FEB 1999 ] DCPC I v/r r> 17 dilution step by addition of diluent so as to produce following the or each dilution step a diluted solution having a higher dilution than that of the solution being diluted; and (c) dosing a compacted mass of particles of a solid carrier with a predetermined amount of the resulting diluted solution so as to produce a solid homeopathic medicinal composition in compacted solid form.
15. A storage container according to claim 14, which contains a unit dosage of the solid homeopathic medicinal composition.
16. A process as claimed in any one of claims 1 to 12 substantially as hereinbefore described with reference to the accompanying diagrammatic drawings of figures 2 and 3.
17. A solid homeopathic medicinal preparation as claimed in claim 13 substantially as hereinbefore described with reference to the accompanying diagrammatic drawings of figures 2 and 3.
18. A storage container as claimed in claim 14 or claim 15 substantially as hereinbefore described with reference to the accompanying diagrammatic drawings of figures 2 and 3. DYNSOL LIMITED —Its Attorneys Baldwin Shelston Waters intellectual property office of n2. t 1 MAY 2000 RECEIVED
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9617658.1A GB9617658D0 (en) | 1996-08-23 | 1996-08-23 | Process |
| PCT/GB1997/002220 WO1998007411A1 (en) | 1996-08-23 | 1997-08-15 | Process to produce solid homeopathic compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ334164A true NZ334164A (en) | 2000-06-23 |
Family
ID=10798836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ334164A NZ334164A (en) | 1996-08-23 | 1997-08-15 | Process to produce solid homeopathic compositions |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0920303A1 (en) |
| JP (1) | JP2001500119A (en) |
| AU (1) | AU727171B2 (en) |
| BR (1) | BR9711349A (en) |
| CA (1) | CA2263872A1 (en) |
| GB (1) | GB9617658D0 (en) |
| NZ (1) | NZ334164A (en) |
| WO (1) | WO1998007411A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6575183B2 (en) * | 2001-08-09 | 2003-06-10 | Benson Tung | Tiltable and rotatable canopy frame for a sunshade |
| EP2910240B1 (en) * | 2014-02-25 | 2021-07-07 | Biologische Heilmittel Heel GmbH | Method for the manufacture of globules |
| FR3049346B1 (en) | 2016-03-23 | 2024-05-17 | Anaquant | SOLUBLE BEADS FOR PREPARING SOLUTIONS |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2617463B2 (en) * | 1987-07-03 | 1989-12-08 | Dolisos Labo Pharmaco Homeopat | CAP FOR CLOSING TUBES AND VIALS, PARTICULARLY FOR PHARMACEUTICAL PRODUCTS |
| CH670766A5 (en) * | 1986-04-12 | 1989-07-14 | Helmut Dr Dr Med Fichter | Earth radiation elimination device for homeopathic treatment - has respective coils contained in successive compartments along length of wooden housing |
| GB9007945D0 (en) * | 1990-04-07 | 1990-06-06 | Beecham Group Plc | Pharmaceutical formulation |
| DE4201179A1 (en) * | 1992-01-17 | 1993-07-22 | Alfatec Pharma Gmbh | Granulates or pellets comprising dispersion of active agent in hydrophilic macromolecules - are e.g. for treatment of depression, hypertension, rheumatism, etc. |
-
1996
- 1996-08-23 GB GBGB9617658.1A patent/GB9617658D0/en active Pending
-
1997
- 1997-08-15 WO PCT/GB1997/002220 patent/WO1998007411A1/en not_active Ceased
- 1997-08-15 BR BR9711349-2A patent/BR9711349A/en not_active Application Discontinuation
- 1997-08-15 NZ NZ334164A patent/NZ334164A/en unknown
- 1997-08-15 CA CA002263872A patent/CA2263872A1/en not_active Abandoned
- 1997-08-15 AU AU40215/97A patent/AU727171B2/en not_active Ceased
- 1997-08-15 EP EP97937667A patent/EP0920303A1/en not_active Withdrawn
- 1997-08-15 JP JP10510505A patent/JP2001500119A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU4021597A (en) | 1998-03-06 |
| JP2001500119A (en) | 2001-01-09 |
| EP0920303A1 (en) | 1999-06-09 |
| CA2263872A1 (en) | 1998-02-26 |
| BR9711349A (en) | 2000-01-18 |
| GB9617658D0 (en) | 1996-10-02 |
| AU727171B2 (en) | 2000-12-07 |
| WO1998007411A1 (en) | 1998-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU636810B2 (en) | Delivery system for enhanced onset and increased potency | |
| Borins | The dangers of using herbs: what your patients need to know | |
| US4199578A (en) | Composition | |
| AU727171B2 (en) | Process to produce solid homeopathic compositions | |
| AU714261B2 (en) | Homeopathic composition and process for its preparation | |
| Eichner et al. | Comparing therapies for postmenopausal osteoporosis prevention and treatment | |
| RU2199312C1 (en) | Method of preparing medicinal agents in solid form from vegetable extracts | |
| JPH07503468A (en) | Sodium iodide ↑1↑3↑11 capsules | |
| RU95101900A (en) | Medicinal preparation for arthritis treatment and a method of its preparing | |
| NO174453B (en) | Procedure for Preparation of a Binder-Free Celiprolo Hydrochloride Granule Can Be Tabulated | |
| CN109700853A (en) | A kind of composition and its application in the drug of preparation prevention and treatment epilepsy | |
| Klumpp | The new federal food, drug and cosmetic act: A consideration of features that are of particular interest to the medical profession | |
| CN103520225A (en) | Ginkgo leaf capsule and preparation method thereof | |
| Hoffert et al. | A double‐blind controlled study of nifedipine as an abortive treatment in acute attacks of migraine with aura | |
| CS277525B6 (en) | Mixture against migraine | |
| Crosby | Prescribing Iron? Think Small | |
| CN1058392C (en) | Disinfecting anti-inflammatory pill and its preparing method | |
| Haywood et al. | Solutions through compounding: Innovative equipment towards efficiency, safety and quality | |
| Parker | ART. V.--Results of the Quantitative and Qualitative Analysis of Homoepathic Medical Preparations. | |
| CN1100939A (en) | Lianhuangsong pill and capsule and its preparation method | |
| CN1095937A (en) | A kind of medicine for the treatment of breast carcinoma and preparation method thereof | |
| Pervaiz et al. | Characterization and Evaluation of Capsules and Study of QC tests for Capsules | |
| RU2200556C1 (en) | Naltrexone medicinal form | |
| CN1182617A (en) | Medicine for curing epilepsy and preparation method thereof | |
| CN121371049A (en) | Qianliao Shukangtang Muscle-Relaxing and Bone-Penetrating Health Plaster |